The Texas Health and Human Services Commission (HHSC) will conduct a public hearing to receive comments on the proposed amendment to §354.1901, §354.1921, §354.1923, and §354.1927 under Title 1, Part 15, Chapter 354, Subchapter F, Division 6, Pharmacy Claims and Additions, Retentions and Deletions to the Texas Drug Code Index.

The Health and Human Services Commission is proposing to amend the Medicaid Vendor Drug Program drug pricing rules to clarify them, thereby standardizing pharmaceutical manufacturers’ price reporting.  These proposed rule amendments will improve administrative efficiency by clarifying pharmaceutical manufacturers’ responsibilities and improving the drug price reporting process. 

Written Comments.  Written comments on the proposed amendments to the rule may be submitted to Stacey Johnston, Policy Analyst, Medicaid/Children’s Health Insurance Program Division, HHSC, at PO Box 85200, Austin, Texas 78708-5200, Mail Code H-310; by fax to 512-491-1953 or by email to Stacey.Johnston@hhsc.state.tx.us within 30 days of publication of this proposal in the Texas Register.